Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco S&P 500 Momentum ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Invesco S&P 500 Momentum ETF trades at $150.7. Which is the better fit depends on your goals.
| ADPT | SPMO | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $161.66 |
52-Week Low | $10.24 | $107.84 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPMO trades at $152.98, up 1.43% with neutral technical signals despite bullish moving averages. The ETF shows strong momentum performance with 7.5% June gains and 44.4% Q2 returns, heavily weighted toward technology stocks (55%) including AI beneficiaries. Recent institutional activity shows mixed positioning with several advisors increasing stakes while others reduced exposure.
Outlook remains constructive given AI-driven momentum strength, though elevated valuations and potential rotation risks warrant monitoring. The ETF's rules-based methodology targeting top S&P 500 momentum performers positions it for continued growth, but concentration in technology exposes it to sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
